Medtide (HKG:3880) completed the acquisition of a parcel of industrial land and property in Hangzhou City, China, a Thursday Hong Kong bourse filing said.
The land and property are proposed to be used in phase I of the company's large-scale peptide and oligonucleotide CDMO production base project.
The company plans to construct a large-scale peptide active pharmaceutical ingredients production line under the project with an estimated designed annual production capacity of 3 to 5 tonnes.
Further expansion using an adjacent land parcel to develop a large-scale CDMO production park is also part of the company's plan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments